Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00208026 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome
A Phase 1 study of Netherton Syndrome, sponsored by Children's Hospital of Philadelphia.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
- 1
- Study location
NCT00208026 is a Phase 1 study of Netherton Syndrome that has completed, run by Children's Hospital of Philadelphia. The registered enrollment target is 3 participants, below the 28-participant average among 6 other Netherton Syndrome trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00208026, a Phase 1 study of Netherton Syndrome, has completed, sponsored by Children's Hospital of Philadelphia.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
- 1
- Study location
Study Summary
Netherton syndrome is a genetic condition that can result in abnormal skin functioning. People with this condition often have red and scaling skin; sparse or short hair; and problems with absorption of medicines or chemicals that are applied to the skin. If these chemicals are absorbed at a high level, they may cause health problems. Elidel (pimecrolimus) is a new medicine that is available as a cream. It has been shown to help improve the appearance of the skin in patients with another skin condition known as atopic dermatitis, and is approved by the United States (US) Food and Drug Administration for use in children with mild to moderate atopic dermatitis. The purpose of this study is to determine if Elidel is safe, to see whether the medication is absorbed through the skin, and to see if side effects are associated with its use in children with Netherton syndrome.
Conditions Studied
Interventions
- DRUG Pimecrolimus 1% Cream
Study Locations (1)
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2005-09 |
| Est. Completion | 2008-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00208026
The ClinicalTrials.gov registry entry for NCT00208026 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 28-participant average among 6 other Netherton Syndrome trials with a reported enrollment target (89% lower). The listed sponsor is Children's Hospital of Philadelphia, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Netherton Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Pimecrolimus 1% Cream is the first listed.
NCT00208026 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00208026 about?
NCT00208026 is a clinical study titled "Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome". Netherton syndrome is a genetic condition that can result in abnormal skin functioning. People with this condition often have red and scaling skin; sparse or short hair; and problems with absorption of medicines or chemicals that are applied to the skin. If these chemicals are absorbed at a high lev...
What is the current status of trial NCT00208026?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2005-09. Estimated completion is 2008-03.
What conditions does trial NCT00208026 study?
This clinical trial studies the following conditions: Netherton Syndrome.
What interventions are being tested in trial NCT00208026?
The interventions under investigation include: Pimecrolimus 1% Cream (DRUG).
Who is sponsoring clinical trial NCT00208026?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00208026 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Netherton Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome
RECRUITING · Phase 1
-
A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725
RECRUITING · Phase 1
-
Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome
RECRUITING · Phase 2
-
Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome
RECRUITING · Phase 2
-
Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome
ACTIVE NOT RECRUITING · Phase 2
-
The Efficacy and Safety of Secukinumab in Patients With Ichthyoses
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.